top of page
grain_2.png

RE-IMAGINE
MENTAL HEALTHCARE 

Transforming neuroscience-based innovation into accessible mental health therapy to help change lives.

arrow.png

GrayMatters Health is leading a transformation by empowering mental healthcare professionals with a neuroscience-based technology that augments standard-of-care therapies to improve patient outcomes and patient lives. This is all based on the world’s first PTSD treatment based on a digital biomarker of brain activity associated with mental health disorders.

​

Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct to psychotherapy and pharmacotherapy for post-traumatic stress disorder (PTSD). The procedure is a new concept –  digitizing brain activity associated with PTSD, giving patients an active role in learning to control brain biomarker activity and improve their symptoms.

PRISM EMPOWERS

IT IS SCIENCE-BASED‭.‬

Prism’s amygdala-based biomarker technology

has been extensively researched.

IT FITS YOUR CLINIC

Installation and training in the morning and treat patients that same afternoon. Can be operated by a non-MD.

IT WORKS‭.‬

In the clinical trial, 67% of patients overall showed clinically significant symptom improvement and 32% were in remission three months after treatment.

PTSD IS PERSONAL

By gamifying brain activity associated with PTSD, patients take an active role in improving their symptoms.

IT IS SAFE‭.‬

Only mild side effects were reported which self-resolved post treatment. 

PATIENTS LIKE IT‭.‬

Prism does not expose patients to trauma and  studies have shown
90% compliance.

IMPACT ON PATIENTS

" I feel that I automatically respond better."


Prism Patient​

SIGN UP FOR NEWSLETTER

Thanks for subscribing!

bottom of page